Production (Stage)
Lexicon Pharmaceuticals, Inc.
LXRX
$0.7667
$0.04976.93%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 8.41% | -13.15% | -37.08% | -54.61% | -75.34% |
Total Depreciation and Amortization | -3.41% | -3.61% | 9.02% | 24.41% | 36.28% |
Total Amortization of Deferred Charges | -14.66% | 4.00% | 37.38% | 107.09% | 106.52% |
Total Other Non-Cash Items | -89.84% | -51.09% | -28.19% | -46.34% | -10.44% |
Change in Net Operating Assets | 221.18% | 435.46% | -114.88% | -169.23% | -2,349.54% |
Cash from Operations | 9.70% | -10.43% | -56.36% | -76.85% | -91.06% |
Capital Expenditure | -364.41% | -119.36% | 67.54% | 79.66% | 85.18% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 179.32% | 71.00% | 78.11% | 3.74% | -224.12% |
Cash from Investing | 178.62% | 69.21% | 77.88% | 4.81% | -215.63% |
Total Debt Issued | -- | -- | -100.00% | -100.00% | 102.11% |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -100.00% | -99.94% | -99.94% | -99.96% | 47.58% |
Repurchase of Common Stock | 69.24% | -69.57% | -57.56% | -118.83% | -118.83% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -126.75% | -- | -- | -- | -- |
Cash from Financing | -100.38% | 26.81% | 12.02% | -22.12% | 262.54% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -147.67% | 285.05% | 488.74% | -182.47% | 310.31% |